Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Cost of Revenue (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of Cost of Revenue data on record, last reported at $635994.0 in Q4 2025.

  • For Q4 2025, Cost of Revenue fell 2.28% year-over-year to $635994.0; the TTM value through Dec 2025 reached $3.2 million, up 1.43%, while the annual FY2025 figure was $3.2 million, 7.46% down from the prior year.
  • Cost of Revenue reached $635994.0 in Q4 2025 per INM's latest filing, down from $716962.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $1.3 million in Q2 2023 and bottomed at $127308.0 in Q1 2022.
  • Average Cost of Revenue over 5 years is $668484.4, with a median of $728056.0 recorded in 2025.
  • Peak YoY movement for Cost of Revenue: surged 560.93% in 2023, then tumbled 37.99% in 2024.
  • A 5-year view of Cost of Revenue shows it stood at $153537.0 in 2021, then skyrocketed by 120.55% to $338620.0 in 2022, then skyrocketed by 170.53% to $916058.0 in 2023, then decreased by 28.96% to $650813.0 in 2024, then fell by 2.28% to $635994.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $635994.0 in Q4 2025, $716962.0 in Q3 2025, and $728056.0 in Q2 2025.